| Date Filed | Type | Description |
| 09/25/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 09/09/2019 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 08/26/2019 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 08/20/2019 |
SC 13D/A
| BP Peptides, LLC reports a 39% stake in Capstone Therapeutics Corp. |
| 08/13/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 07/10/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/03/2019 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 07/03/2019 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 05/31/2019 |
SC 13E3
| Form SC 13E3 - Going private transaction by certain issuers: |
| 05/31/2019 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/13/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 03/22/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/21/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/19/2019 |
SC 13D/A
| BP Peptides, LLC reports a 38% stake in Capstone Therapeutics Corp. |
| 03/19/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/13/2019 |
SC 13G/A
| SUBIN NEIL S reports a 13.9% stake in Capstone Therapeutics Corp. |
| 02/11/2019 |
SC 13G
| Alimco Financial Corp reports a 0.2% stake in Capstone Therapeutics Corp. |
| 02/04/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 12/28/2018 |
4
| SUBIN NEIL S (10% Owner) has filed a Form 4 on Capstone Therapeutics Corp.|
Txns:
| Sold 206,000 shares
@ $0.052, valued at
$10.7k
Bought 103,000 shares
@ $0.052, valued at
$5.4k
|
|
| 11/20/2018 |
SC 13D/A
| BP Peptides, LLC reports a 37.5% stake in Capstone Therapeutics Corp. |
| 11/06/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 08/13/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 05/18/2018 |
SC 13D/A
| BP Peptides, LLC reports a 36.4% stake in Capstone Therapeutics Corp. |
| 05/11/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 05/07/2018 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"License Agreement dated May 2, 2018, by and between LipimetiX Development, Inc. and ANJI Pharmaceuticals Inc",
"LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China NATICK, Mass., May 07, 2018 -- LipimetiX Development, Inc. announced today that Anji Pharmaceuticals, Inc. has entered a licensing agreement for the LipimetiX platform of peptides for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. The Anji Pharma’s license provides exclusive rights to and use of the LipimetiX patent portfolio of Apo E mimetic peptides and formulations in the above-mentioned territory. Terms include an upfront licensing payment to LipimetiX of US$2.0 million, multiple additional cash payments up..." |
|
| 02/28/2018 |
10-K
| Annual Report for the period ended December 31, 2017 |
| 02/01/2018 |
4
| Lipman Matthew E. (10% Owner) has filed a Form 4 on Capstone Therapeutics Corp.|
Txns:
| Acquired 1 options to buy
@ $0.075, valued at
$0.1 |
|
| 02/01/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/01/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/23/2018 |
SC 13G
| SUBIN NEIL S reports a 14.1% stake in Capstone Therapeutics Corp. |
| 01/22/2018 |
3
| SUBIN NEIL S (10% Owner) has filed a Form 3 on Capstone Therapeutics Corp. |
|